On June 11, 2013, the DEA announced that Walgreens Corporation agreed to pay $80 million in civil penalties, the largest settlement in DEA history. This settlement resolves both the DEA’s administrative actions against Walgreens and the U.S. Attorney’s Office’s civil penalty investigation. In addition to the civil penalty, Walgreens agreed to a two year
Upcoming DEA Conferences
The DEA has announced an upcoming Manufacturer/Importer/Exporter Conference to be held in June 2013 at the National Harbor, Gaylord National Resort & Convention Center. “The purpose of this conference is to provide a forum to present federal laws and regulations that affect the pharmaceutical and chemical manufacturing, importing, and exporting industry and to discuss practices
DEA’s Uneasy Relationship with Oxycodone
DEA’s position on oxycodone is clear — more or less. In DEA’s letter to FDA supporting a petition to restrict the approved labeled use of oxycodone to “severe pain,” DEA said that “abuse of prescription opioids have increased markedly over the past decade.” In the letter DEA also expressed support for the legitimate and beneficial
Legitimate Pain Clinics?
DEA is okay with some pain management clinics.
A DEA official told an industry conference that some pain management clinics are legitimate. When describing the proliferation of pain management clinics, DEA Associate Deputy Administrator Alan Santos told the audience at HDMA’s Distribution Management Conference and Technology Expo that prior to the rapid growth of pain
Significant Shift in Drug Diversion
Go West, young man!
The Wall Street Journal published a very interesting article on the shift in drug diversion trends within the United States. DEA has very publicly focused its enforcement efforts on South Florida pill mills as well as other problematic locations in the Eastern United States. According to information obtained by the Wall
DEA Compliance Programs
Do you see what DEA sees? The Controlled Substances Act and the DEA’s regulations are unambiguous and DEA’s interactions with registrants are predictable, right? Well, not always. However, the maze of DEA compliance issues can be made a little less complex by understanding the Agency’s perspective on issues. In the DEA Chronicles you will find